Invesco Ltd. Sells 26,554 Shares of Janux Therapeutics, Inc. $JANX

Key Points

• Invesco Ltd. has reduced its stake in Janux Therapeutics, Inc. by 9.3%, now holding about 258,108 shares worth $6.97 million.
• Multiple institutional investors, including GAMMA Investing LLC and US Bancorp DE, significantly increased their stakes in Janux Therapeutics, with GAMMA boosting its position by 1,574%.
• Janux Therapeutics reported an EPS of ($0.55) for the last quarter, missing the consensus estimate by ($0.07), and is expected to post a yearly EPS of ($1.38).

Invesco Ltd. cut its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 9.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 258,108 shares of the company's stock after selling 26,554 shares during the quarter. Invesco Ltd. owned 0.44% of Janux Therapeutics worth $6,969,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after acquiring an additional 1,574 shares in the last quarter. US Bancorp DE raised its stake in shares of Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after acquiring an additional 1,658 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $59,000. FNY Investment Advisers LLC raised its stake in shares of Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after acquiring an additional 2,425 shares in the last quarter. Finally, KBC Group NV purchased a new position in shares of Janux Therapeutics during the first quarter worth approximately $66,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Down 1.4%

Shares of JANX stock traded down $0.33 during mid-day trading on Friday, reaching $22.72. 456,346 shares of the company's stock traded hands, compared to its average volume of 814,947. Janux Therapeutics, Inc. has a 12 month low of $21.97 and a 12 month high of $71.71. The company has a market cap of $1.37 billion, a P/E ratio of -12.62 and a beta of 2.86. The company's 50-day moving average price is $24.52 and its 200-day moving average price is $27.22.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). Equities analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Piper Sandler began coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They set an "overweight" rating and a $42.00 price target on the stock. Raymond James Financial began coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $86.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.